[1] Mazzaferro V, Droz Dit Busset M, Bhoori S. Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better. Hepatology, 2018, 68: 775-777.
[2] Agopian VG, Harlander-Locke MP, Markovic D, et al. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce alpha-Fetoprotein. JAMA Surg, 2017, 152: 55-64.
[3] Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg, 2007, 245: 435-442.
[4] Agopian VG, Harlander-Locke MP, Ruiz RM, et al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg, 2017, 266: 525-535. |
